Shakira sells MU 29.68: Nektar Therapeutics Harnesses The Power Of AstraZeneca To Move Movantik
Several years ago, there was trouble in this peripherally acting mu-opioid receptor antagonist class of OIC treatments. Salix' (NASDAQ:SLXP) Relistor and Cubist's (NASDAQ:CBST) Entereg, though not approved for chronic pain patients, were causing some acute ... ...
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home